Update on PD-1/PD-L1 Inhibitors in Extensive-Stage Small Cell Lung Cancer
PD-1/PD-L1 inhibitors offer an improvement over standard of care in SCLC, but there is still a long way to go.
PD-1/PD-L1 inhibitors offer an improvement over standard of care in SCLC, but there is still a long way to go.
The signaling pathways detected may shed light on new treatment strategies.
A survey presented during ASCO20 found that patients who considered themselves adequately informed felt “in control” most days.